Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » Senate moves motion to establish rare cancer inquiry

Senate moves motion to establish rare cancer inquiry

  • June 26, 2023

Senator, Wendy Askew has moved a motion to conduct a Senate Inquiry regarding Equitable Access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer. 

The Terms of Reference for the inquiry are:

Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer, with particular reference to:

a. barriers to screening and diagnosis, including the impact of factors such as:

i. geographic location,
ii. cost,
iii. cultural and language barriers,
iv. type of cancer, and
v. availability of treating practitioners;

b. barriers to accessing appropriate treatment;

c. the adequacy of support services after diagnosis;

d. the adequacy of Commonwealth funding for research into rare, less common, and neuroendocrine cancer; and

e. any other related matters.

You can read Senator Wendy Askew’s full press release HERE.

If you have experienced any of these factors and would like to help support this landmark inquiry please register your details below and we will be in touch shortly with a template and further instructions to assist in your submission.

Register your details below

Share this post

Recent posts

Be the Voice for NET Patients in WA – Join Our CAG Team

June 10, 2025

BioPharmaDispatch 2025: Putting NETs on the National Agenda

May 27, 2025

WA Cancer Forum

May 27, 2025

ANZSNM 55th annual conference in Melbourne – Australia

May 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousGlobal Gaps in Access to Diagnostics and Treatment for Neuroendocrine Cancer Patients published in Journal of Neuroendocrinology
NextEquitable access for all NET patientsNext

Related Posts

Be the Voice for NET Patients in WA – Join Our CAG Team

Call out for a consumer advisory representative from Western Australia (voluntary position) Are you from Western Australia? Have you experienced a diagnosis of a Neuroendocrine

BioPharmaDispatch 2025: Putting NETs on the National Agenda

BioPharmaDispatch 2025: Putting NETs on the National Agenda NeuroEndocrine Cancer Australia was proud to attend the BioPharmaDispatch 2025 Conference in Sydney this month, represented by

WA Cancer Forum

The Cancer Network WA, in collaboration with the WA Clinical Oncology Group at Cancer Council WA,  held its second annual one-day symposium “Cancer Network Forum

ANZSNM 55th annual conference in Melbourne – Australia

Thank you to Simone Leyden AM, Director Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals Limited ARCS Australia, for organising sponsorship for a group

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin